{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:12:54Z","timestamp":1788786774528,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41409-025-02511-7","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T01:18:30Z","timestamp":1737508710000},"page":"467-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes"],"prefix":"10.1038","volume":"60","author":[{"given":"Cuiyan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0267-1081","authenticated-orcid":false,"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-6792","authenticated-orcid":false,"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6124-6050","authenticated-orcid":false,"given":"Yingjun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-7945","authenticated-orcid":false,"given":"Xiaodong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-2231","authenticated-orcid":false,"given":"Yuqian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1253-7465","authenticated-orcid":false,"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2511_CR1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.beha.2014.11.004","volume":"28","author":"DV Babushok","year":"2015","unstructured":"Babushok DV, Bessler M. Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol. 2015;28:55\u201368.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2511_CR2","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","volume":"39","author":"R Nakamura","year":"2021","unstructured":"Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021;39:3328\u201339.","journal-title":"J Clin Oncol"},{"key":"2511_CR3","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","volume":"39","author":"N Kr\u00f6ger","year":"2021","unstructured":"Kr\u00f6ger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, et al. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). J Clin Oncol. 2021;39:3318\u201327.","journal-title":"J Clin Oncol"},{"key":"2511_CR4","doi-asserted-by":"crossref","first-page":"a028308","DOI":"10.1101\/cshperspect.a028308","volume":"7","author":"G Chillemi","year":"2017","unstructured":"Chillemi G, Kehrloesser S, Bernassola F, Desideri A, D\u00f6tsch V, Levine AJ, et al. Structural Evolution and Dynamics of the p53 Proteins. Cold Spring Harb Perspect Med. 2017;7:a028308.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2511_CR5","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"R Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K, Bar-Natan M, P\u00e9rez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705\u201312.","journal-title":"Blood."},{"key":"2511_CR6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","volume":"38","author":"C Bally","year":"2014","unstructured":"Bally C, Ad\u00e8s L, Renneville A, Sebert M, Eclache V, Preudhomme C, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014;38:751\u20135.","journal-title":"Leuk Res"},{"key":"2511_CR7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","volume":"30","author":"DA Sallman","year":"2016","unstructured":"Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30:666\u201373.","journal-title":"Leukemia."},{"key":"2511_CR8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","volume":"4","author":"G Montalban-Bravo","year":"2020","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020;4:482\u201395.","journal-title":"Blood Adv"},{"key":"2511_CR9","doi-asserted-by":"crossref","first-page":"216767","DOI":"10.1016\/j.canlet.2024.216767","volume":"588","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen W, Yu J, Pei S, Zhang Q, Shi J, et al. TP53 in MDS and AML: Biological and clinical advances. Cancer Lett. 2024;588:216767.","journal-title":"Cancer Lett"},{"key":"2511_CR10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/hematology.2022000354","volume":"2022","author":"J Versluis","year":"2022","unstructured":"Versluis J, Lindsley RC. Transplant for TP53-mutated MDS and AML: because we can or because we should? Hematology Am Soc Hematol Educ Program. 2022;2022:522\u20137.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2511_CR11","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3324\/haematol.2017.172544","volume":"102","author":"I Aldoss","year":"2017","unstructured":"Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, Telatar M, et al. Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status. Haematologica. 2017;102:2030\u20138.","journal-title":"Haematologica."},{"key":"2511_CR12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ijc.34323","volume":"152","author":"C Zhou","year":"2023","unstructured":"Zhou C, Zheng F, Xu L, Zhang X, Chang Y, Mo X, et al. Mutation of the TP53 gene in acute lymphoblastic leukemia does not affect survival outcomes after haploidentical hematopoietic stem cell transplantation. Int J Cancer. 2023;152:977\u201385.","journal-title":"Int J Cancer"},{"key":"2511_CR13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bjh.18538","volume":"200","author":"T Huang","year":"2023","unstructured":"Huang T, Xu L, Zhang X, Chang Y, Mo X, Sun Y, et al. Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia. Br J Haematol. 2023;200:494\u2013505.","journal-title":"Br J Haematol"},{"key":"2511_CR14","first-page":"528","volume":"40","author":"WM Chen","year":"2019","unstructured":"Chen WM, Liu H, Li LD, Long LY, Lai YY, Shi HX, et al. [Clinical, molecular and cytogenetic characteristics of newly diagnosed adult acute myeloid patients with TP53 gene mutation]. Zhonghua Xue Ye Xue Za Zhi. 2019;40:528\u201331.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2511_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2478\/jtim-2023-0111","volume":"11","author":"Z Xu","year":"2023","unstructured":"Xu Z, Mo X, Kong Y, Wen Q, Han T, Lyu M, et al. Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: A phase 2 trial. J Transl Int Med. 2023;11:255\u201364.","journal-title":"J Transl Int Med"},{"key":"2511_CR16","doi-asserted-by":"crossref","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"},{"key":"2511_CR17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood."},{"key":"2511_CR18","first-page":"302","volume":"27","author":"YR Liu","year":"2006","unstructured":"Liu YR, Zhang LP, Chang Y, Cheng YF, Fu JY, Li LD, et al. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2006;27:302\u20135.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2511_CR19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017;376:536\u201347.","journal-title":"N Engl J Med"},{"key":"2511_CR20","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bmt.2015.110","volume":"50","author":"M Kim","year":"2015","unstructured":"Kim M, Yahng SA, Kwon A, Park J, Jeon YW, Yoon JH, et al. Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation. Bone Marrow Transplant. 2015;50:1132\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"2511_CR21","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","volume":"34","author":"MG Della Porta","year":"2016","unstructured":"Della Porta MG, Gall\u00ec A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, et al. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2016;34:3627\u201337.","journal-title":"J Clin Oncol"},{"key":"2511_CR22","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","volume":"32","author":"R Bejar","year":"2014","unstructured":"Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32:2691\u20138.","journal-title":"J Clin Oncol"},{"key":"2511_CR23","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","volume":"131","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, et al. Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations. Blood. 2018;131:2989\u201392.","journal-title":"Blood."},{"key":"2511_CR24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10238-023-01287-8","volume":"24","author":"F Tang","year":"2024","unstructured":"Tang F, Wang Y, Wang Y, Jin J, Han W, Chen Y, et al. The clinical outcomes of haploidentical stem cell transplantation (haplo-HSCT) for patients with therapy-related myelodysplastic syndrome: comparable to de novo myelodysplastic syndrome. Clin Exp Med. 2024;24:33.","journal-title":"Clin Exp Med"},{"key":"2511_CR25","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","volume":"136","author":"DA Sallman","year":"2020","unstructured":"Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136:2812\u201323.","journal-title":"Blood."},{"key":"2511_CR26","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41423-020-00597-1","volume":"18","author":"H Guo","year":"2021","unstructured":"Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH, et al. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol. 2021;18:1172\u201385.","journal-title":"Cell Mol Immunol"},{"key":"2511_CR27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/bmt.2011.213","volume":"47","author":"Y Wang","year":"2012","unstructured":"Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH, et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched\/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant. 2012;47:1099\u2013104.","journal-title":"Bone Marrow Transplant"},{"key":"2511_CR28","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","volume":"119","author":"CH Yan","year":"2012","unstructured":"Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119:3256\u201362.","journal-title":"Blood."},{"key":"2511_CR29","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139:2347\u201354.","journal-title":"Blood."},{"key":"2511_CR30","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","volume":"132","author":"T Kim","year":"2018","unstructured":"Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY, et al. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. Blood. 2018;132:1604\u201313.","journal-title":"Blood."},{"key":"2511_CR31","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","volume":"7","author":"J Loke","year":"2023","unstructured":"Loke J, McCarthy N, Jackson A, Siddique S, Hodgkinson A, Mason J, et al. Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS. Blood Adv. 2023;7:3666\u201376.","journal-title":"Blood Adv"},{"key":"2511_CR32","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-016-2706-y","volume":"95","author":"XD Mo","year":"2016","unstructured":"Mo XD, Qin YZ, Zhang XH, Xu LP, Wang Y, Yan CH, et al. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2016;95:1233\u201340.","journal-title":"Ann Hematol"},{"key":"2511_CR33","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/bjh.19247","volume":"204","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Fleti F, Chan O, Al Ali NH, Al-Kali A, Begna KH, et al. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Br J Haematol. 2024;204:1243\u20138.","journal-title":"Br J Haematol"}],"updated-by":[{"DOI":"10.1038\/s41409-025-02526-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02511-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02511-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02511-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T04:24:32Z","timestamp":1743827072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02511-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2511"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02511-7","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41409-025-02526-0","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: \"In this article the Funding section has been updated\".","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41409-025-02526-0","URL":"https:\/\/doi.org\/10.1038\/s41409-025-02526-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Institutional Review Board of Peking University approved this study, and all subjects and donors gave written informed consent. This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}